• 1
    Garcia-Sanz R, Orfao A, Gonzalez M, et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood 1999;93:10321037.
  • 2
    Dimopoulos MA, Palumbo A, Delasalle KB, et al. Primary plasma cell leukaemia. Br J Haematol 1994;88:754759.
  • 3
    Bernasconi C, Castelli G, Pagnucco G, et al. Plasma cell leukemia: a report on 15 patients. Eur J Haematol 1989;51(Suppl):7683.
  • 4
    International Myeloma Working Group: Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749757.
  • 5
    Noel P, Kyle RA. Plasma cell leukemia: an evaluation of response to therapy. Am J Med 1987;83:10621068.
  • 6
    Vela-Ojeda J, Garcia-Ruiz Esparza MA, Rosas-Cabral A, et al. Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia. Ann Hematol 2002;81:362367.
  • 7
    Hayman SR, Fonseca R. Plasma cell leukemia. Curr Treat Options Oncol 2001;2:202216.
  • 8
    Foa P. Sulla produzione cellulare nell infiammazione ed in altri processi analoghi specialmente in cio che si riferisce alle plasmacellule. Folia Haematol (Leipz) 1904;1:166167.
  • 9
    Gluzinski A, Reichenstein M. Myeloma und Leucaemia lymphatica plasmocellularis. Wien Klin Wochensch 1906;19:336339.
  • 10
    Kyle RA, Maldonado JE, Bayrd ED. Plasma cell leukemia. Report on 17 cases. Arch Intern Med 1974;133:813818.
  • 11
    Pellat-Deceunynck C, Barille S, Jego G, et al. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia 1998;12:19771982.
  • 12
    Avet-Loiseau H, Daviet A, Brigaudeau C, et al. Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myelome and the Groupe Français de Cytogenetique Hematologique. Blood 2001;97:822825.
  • 13
    Woodruff RK, Malpas JS, Paxton AM, et al. Plasma cell leukemia (PCL): a report on 15 patients. Blood 1978;52:839845.
  • 14
    Toma VA, Retief FP, Potgieter GM, et al. Plasma cell leukaemia. Diagnostic problems in our experience with 11 cases. Acta Haematol 1980;63:136145.
  • 15
    Costello R, Sainty D, Bouabdallah R, et al. Primary plasma cell leukaemia: a report of 18 cases (review). Leuk Res 2001;25:103107.
  • 16
    McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma cell-leukaemia and myeloma. Lancet 1983;2(8354):822824.
  • 17
    Buckner CD, Fefer A, Bensinger WI, et al. Marrow transplantation for malignant plasma cell disorders: summary of the Seattle experience. Eur J Haematol 1989;51(Suppl):186190.
  • 18
    De Bock R, Nobels F, Schoemaker I, et al. Allogeneic bone marrow transplantation for plasma cell leukemia following melphalan, cyclophosphamide and total body irradiation. Bone Marrow Transplant 1989;4:331.
  • 19
    Mak YK, Chan CH, Chen YT, et al. Consolidation therapy with autologous blood stem cell transplantation in a patient with primary plasma cell leukaemia. Clin Lab Haematol 2003;25:5558.
  • 20
    Sajeva MR, Greco MM, Cascavilla N, et al. Effective autologous peripheral blood stem cell transplantation in plasma cell leukemia followed by T-large granular lymphocyte expansion: a case report. Bone Marrow Transplant 1996;18:225227.
  • 21
    Hovenga S, de Wolf JT, Klip H, et al. Consolidation therapy with autologous stem cell transplantation in plasma cell leukemia after VAD, high-dose cyclophosphamide and EDAP courses: a report of three cases and a review of the literature. Bone Marrow Transplant 1997;20:901904.
  • 22
    Sica S, Chiusolo P, Salutari P, et al. Long-lasting complete remission in plasma cell leukemia after aggressive chemotherapy and CD34-selected autologous peripheral blood progenitor cell transplant: molecular follow-up of minimal residual disease. Bone Marrow Transplant 1998;22:823825.
  • 23
    Leleu X, Jouet JP, Plantier I, et al. Isolated neurological relapse following stem cell transplantation in plasma cell leukemia: a report of two cases. Leukemia 1999;13:307309.
  • 24
    Panizo C, Rifon J, Rodriguez-Wilhelmi P, et al. Long-term survival in primary plasma cell leukemia after therapy with VAD, autologous blood stem cell transplantation and interferon-alpha. Acta Haematol 1999;101:193196.
  • 25
    Ghosh K, Madkaikar M, Iyer Y, et al. Systemic capillary leak syndrome preceding plasma cell leukaemia. Acta Haematol 2001; 106:118121.
  • 26
    Buchler T, Ferra C, Domingo A, et al. Long-term disease-free survival in a primary plasma cell leukemia treated by VAD, autologous PBSC transplantation, and IFN-alpha. Am J Hematol 2002; 71:62.
  • 27
    Cernelc P, Malkar U. Maintenance treatment of primary plasma cell leukemia with interferon alpha. Transplant Proc 2002;34:29292930.
  • 28
    Ghosh K, Gosavi S, Pathare A, et al. Low cost autologous peripheral blood stem cell transplantation performed in a municipal hospital for a patient with plasma cell leukaemia. Clin Lab Haematol 2002;24:187190.
  • 29
    Gemmel C, Cremer FW, Weis M, et al. Anti-CD20 antibody as consolidation therapy in a patient with primary plasma cell leukemia after high-dose therapy and autologous stem cell transplantation. Ann Hematol 2002;81:119123.
  • 30
    Myeloma Trialists' Collaborative Group Secretariat. Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 2001; 113:10201034.
  • 31
    Björkstrand B, Svensson H, Goldschmidt H, et al. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 2001;27:511515.
  • 32
    Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult lymphocytic leukemia. J Clin Oncol 2000;18:547561.
  • 33
    Romaguera JE, Khouri IF, Kanatarjian HM, et al. Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients. Leuk Lymphoma 2000;39:7785.
  • 34
    Luft T, Moos M, Goldschmidt H, et al. Dissociation of graft-versus-haematopoiesis and graft-versus-myeloma effects in patients with rapidly progressive multiple myeloma. Br J Haematol 2003;123:646653.
  • 35
    Maloney DG, Molina AJ, Sahebi F, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102:34473454.
  • 36
    Barlogie B, Shaughnessy J, Tricot G, et al. Treatment of multiple myeloma. Blood 2004;103:2032.
  • 37
    Blade J, Kyle, RA. Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. Hematol Oncol Clin North Am 1999;13(6):12591272.